The company specializes in developing the ViewSite Brain Access System, which reduces brain tissue trauma caused by excessive pressure during surgery. Additionally, Vycor Medical offers non-invasive rehabilitation therapies for patients with neurological brain damage resulting from strokes. The company operates through two segments: Vycor Medical, focusing on neurosurgical devices, and NovaVision, focusing on neurostimulation therapies and diagnostic devices for visual field loss. Most of their revenue comes from the Vycor Medical segment in the US. Vycor Medical aims to optimize surgical site access, minimize patient risk, and enhance recovery for neurological procedures. In 2012, the company went public with a valuation of $33.66 million.